Loss of β-catenin promotes chondrogenic differentiation of aortic valve interstitial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 12, 2014, Pages 2601-2608

  Fang, Ming ^a   Alfieri, Christina M ^a   Hulin, Alexia ^a   Conway, Simon J ^b   Yutzey, Katherine E ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aortic valve; Chondrogenesis; Heart valve disease; Proteoglycans; Wnt signaling pathway

Indexed keywords

7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; AGGRECAN; BETA CATENIN; COLLAGEN TYPE 10; COLLAGEN TYPE 10A1; COLLAGEN TYPE 2; COLLAGEN TYPE 2A1; PROTEOGLYCAN; SCLEROPROTEIN; TRANSCRIPTION FACTOR RUNX2; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG; WNT PROTEIN; AVIAN PROTEIN; CTNNB1 PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA VALVE; ARTICLE; CELL DIFFERENTIATION; CHONDROGENESIS; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LEYDIG CELL; MEDIATOR; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PROTEIN DEPLETION; PROTEIN INDUCTION; VALVULAR HEART DISEASE; VALVULAR INTERSTITIAL CELL; WNT SIGNALING PATHWAY; ANIMAL; CHICK EMBRYO; CONGENITAL HEART MALFORMATION; CYTOLOGY; DEFICIENCY; EMBRYOLOGY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; AORTIC VALVE; AVIAN PROTEINS; BETA CATENIN; CELL DIFFERENTIATION; CHICK EMBRYO; CHONDROGENESIS; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION; HEART DEFECTS, CONGENITAL; HEART VALVE DISEASES; HUMANS; MICE; MICE, KNOCKOUT; PROTEOGLYCANS; SOX9 TRANSCRIPTION FACTOR; WNT SIGNALING PATHWAY;

EID: 84918778963     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304579     Document Type: Article

References (49)

1. Hinton RB, Yutzey KE. Heart valve structure and function in development and disease. Annu Rev Physiol. 2011;73:29-46.
2. Hayek E, Gring CN, Griffin BP. Mitral valve prolapse. Lancet. 2005; 365:507-518.
3. Guy TS, Hill AC. Mitral valve prolapse. Annu Rev Med. 2012;63:277-292.
4. Hulin A, Deroanne C, Lambert C, Defraigne JO, Nusgens B, Radermecker M, Colige A. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data. Cardiovasc Pathol. 2013;22:245-250.
5. Lincoln J, Lange AW, Yutzey KE. Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol. 2006;294:292-302.
6. Combs MD, Yutzey KE. Heart valve development: regulatory networks in development and disease. Circ Res. 2009;105:408-421.
7. Yang JH, Wylie-Sears J, Bischoff J. Opposing actions of Notch1 and VEGF in post-natal cardiac valve endothelial cells. Biochem Biophys Res Commun. 2008;374:512-516.
8. Chakraborty S, Wirrig EE, Hinton RB, Merrill WH, Spicer DB, Yutzey KE. Twist1 promotes heart valve cell proliferation and extracellular matrix gene expression during development in vivo and is expressed in human diseased aortic valves. Dev Biol. 2010;347:167-179.
9. Li C, Xu S, Gotlieb AI. The response to valve injury. A paradigm to understand the pathogenesis of heart valve disease. Cardiovasc Pathol. 2011;20:183-190.
10. Wirrig EE, Hinton RB, Yutzey KE. Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. J Mol Cell Cardiol. 2011;50:561-569.
11. Cheek JD, Wirrig EE, Alfieri CM, James JF, Yutzey KE. Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease. J Mol Cell Cardiol. 2012;52:689-700.
12. Hurlstone AF, Haramis AP, Wienholds E, Begthel H, Korving J, Van Eeden F, Cuppen E, Zivkovic D, Plasterk RH, Clevers H. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature. 2003;425:633-637.
13. Liebner S, Cattelino A, Gallini R, Rudini N, Iurlaro M, Piccolo S, Dejana E. Beta-catenin is required for endothelial-mesenchymal transformation during heart cushion development in the mouse. J Cell Biol. 2004;166:359-367.
14. Alfieri CM, Cheek J, Chakraborty S, Yutzey KE. Wnt signaling in heart valve development and osteogenic gene induction. Dev Biol. 2010;338:127-135.
15. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, Bonow RO, Spelsberg TC, McCarthy PM, Rahimtoola S.H., Rajamannan NM. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol. 2006;47:1707-1712.
16. Kawakami Y, Rodriguez-León J, Izpisúa Belmonte JC. The role of TGFbetas and Sox9 during limb chondrogenesis. Curr Opin Cell Biol. 2006;18:723-729.
17. Akiyama H, Lefebvre V. Unraveling the transcriptional regulatory machinery in chondrogenesis. J Bone Miner Metab. 2011;29:390-395.
18. Yeung Tsang K, Wa Tsang S, Chan D, Cheah KS. The chondrocytic journey in endochondral bone growth and skeletal dysplasia. Birth Defects Res C Embryo Today. 2014;102:52-73.
19. Lincoln J, Alfieri CM, Yutzey KE. BMP and FGF regulatory pathways control cell lineage diversification of heart valve precursor cells. Dev Biol. 2006;292:292-302.
20. Lincoln J, Kist R, Scherer G, Yutzey KE. Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol. 2007;305:120-132.
21. Peacock JD, Levay AK, Gillaspie DB, Tao G, Lincoln J. Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res. 2010;106:712-719.
22. Peacock JD, Huk DJ, Ediriweera HN, Lincoln J. Sox9 transcriptionally represses Spp1 to prevent matrix mineralization in maturing heart valves and chondrocytes. PLoS One. 2011;6:e26769.
23. Sainger R, Grau JB, Branchetti E, Poggio P, Seefried WF, Field BC, Acker M.A., Gorman RC, Gorman JH 3rd, Hargrove CW 3rd, Bavaria JE, Ferrari G. Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation. J Cell Physiol. 2012;227:2595-2604.
24. Lacerda CMR, MacLea, H.B., Duncan, C.G., Kisiday, J.D., Orton, E.C. Human myxomatous mitral valves exhibit focal expression of cartilagerelated proteins. J Hypertens Cardiol. 2013;1:1-10
25. Grigoryan T, Wend P, Klaus A, Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss-and gain-of-function mutations of beta-catenin in mice. Genes Dev. 2008;22:2308-2341.
26. Lindsley A, Snider P, Zhou H, Rogers R, Wang J, Olaopa M, Kruzynska-Frejtag A, Koushik SV, Lilly B, Burch JB, Firulli AB, Conway SJ. Identification and characterization of a novel Schwann and outflow tract endocardial cushion lineage-restricted periostin enhancer. Dev Biol. 2007;307:340-355.
27. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med. 2004;10:55-63.
28. Huang SM, Mishina YM, Liu S, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461:614-620.
29. Lustig B, Jerchow B, Sachs M, Weiler S, Pietsch T, Karsten U, Van de Wetering M, Clevers H, Schlag PM, Birchmeier W, Behrens J. Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol. 2002;22:1184-1193.
30. Brault V, Moore R, Kutsch S, Ishibashi M, Rowitch DH, McMahon AP, Sommer L, Boussadia O, Kemler R. Inactivation of the betacatenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development. 2001;128:1253-1264.
31. Soriano P. Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat Genet. 1999;21:70-71.
32. Kou I, Ikegawa S. SOX9-dependent and-independent transcriptional regulation of human cartilage link protein. J Biol Chem. 2004;279:50942-50948.
33. Lockhart MM, Wirrig EE, Phelps AL, Ghatnekar AV, Barth JL, Norris R.A., Wessels A. Mef2c regulates transcription of the extracellular matrix protein cartilage link protein 1 in the developing murine heart. PLoS One. 2013;8:e57073.
34. Zhong Z, Zeng XL, Ni JH, Huang XF. Comparison of the biological response of osteoblasts after tension and compression. Eur J Orthod. 2013;35:59-65.
35. Woods A, Wang G, Beier F. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem. 2005;280:11626-11634.
36. Kumar D, Lassar AB. The transcriptional activity of Sox9 in chondrocytes is regulated by RhoA signaling and actin polymerization. Mol Cell Biol. 2009;29:4262-4273.
37. Ikegami D, Akiyama H, Suzuki A, Nakamura T, Nakano T, Yoshikawa H, Tsumaki N. Sox9 sustains chondrocyte survival and hypertrophy in part through Pik3ca-Akt pathways. Development. 2011;138:1507-1519.
38. Leung VY, Gao B, Leung KK, Melhado IG, Wynn SL, Au TY, Dung NW, Lau JY, Mak AC, Chan D, Cheah KS. SOX9 governs differentiation stagespecific gene expression in growth plate chondrocytes via direct concomitant transactivation and repression. PLoS Genet. 2011;7:e1002356.
39. Dy P, Wang W, Bhattaram P, Wang Q, Wang L, Ballock RT, Lefebvre V. Sox9 directs hypertrophic maturation and blocks osteoblast differentiation of growth plate chondrocytes. Dev Cell. 2012;22:597-609.
40. Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005;8:739-750.
41. Hill TP, Später D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell. 2005;8:727-738.
42. Akiyama H, Lyons JP, Mori-Akiyama Y, Yang X, Zhang R, Zhang Z, Deng JM, Taketo MM, Nakamura T, Behringer RR, McCrea PD, de Crombrugghe B. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev. 2004;18:1072-1087.
43. Maatouk DM, DiNapoli L, Alvers A, Parker KL, Taketo MM, Capel B. Stabilization of beta-catenin in XY gonads causes male-to-female sexreversal. Hum Mol Genet. 2008;17:2949-2955.
44. Rajamannan NM, Evans FJ, Aikawa E, Grande-Allen KJ, Demer LL, Heistad DD, Simmons C.A., Masters KS, Mathieu P, O'Brien KD, Schoen FJ, Towler D.A., Yoganathan AP, Otto CM. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation. 2011;124:1783-1791.
45. Kyndt F, Gueffet JP, Probst V, et al. Mutations in the gene encoding filamin A as a cause for familial cardiac valvular dystrophy. Circulation. 2007;115:40-49.
46. Nesta F, Leyne M, Yosefy C, Simpson C, Dai D, Marshall JE, Hung J, Slaugenhaupt SA, Levine R.A. New locus for autosomal dominant mitral valve prolapse on chromosome 13: clinical insights from genetic studies. Circulation. 2005;112:2022-2030.
47. Padang R, Bagnall RD, Semsarian C. Genetic basis of familial valvular heart disease. Circ Cardiovasc Genet. 2012;5:569-580.
48. Orton EC, Lacerda CM, MacLea HB. Signaling pathways in mitral valve degeneration. J Vet Cardiol. 2012;14:7-17.
49. Snider P, Hinton RB, Moreno-Rodriguez R.A., Wang J, Rogers R, Lindsley A, Li F, Ingram D.A., Menick D, Field L, Firulli AB, Molkentin JD, Markwald R, Conway SJ. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res. 2008;102:752-760.